PMID- 31486571
OWN - NLM
STAT- MEDLINE
DCOM- 20210405
LR  - 20210405
IS  - 1522-726X (Electronic)
IS  - 1522-1946 (Linking)
VI  - 96
IP  - 3
DP  - 2020 Sep 1
TI  - Outcomes of extracorporeal membrane oxygenation support in the cardiac 
      catheterization laboratory.
PG  - 547-555
LID - 10.1002/ccd.28492 [doi]
AB  - OBJECTIVES: The aims of this single-center retrospective study were to 
      characterize and determine predictors of 30-day survival in a cohort of patients 
      requiring venoarterial extracorporeal membrane oxygenation (VA-ECMO) supported 
      cardiopulmonary resuscitation (E-CPR) in the cardiac catheterization laboratory 
      (CCL) for cardiac arrest (CA) or refractory cardiogenic shock (CS). BACKGROUND: 
      While safety in the CCL has improved, periprocedural mortality from CA remains 
      high. The application of VA-ECMO is an emerging form of resuscitation with a 
      paucity of data evaluating its use in the CCL for CA or CS. METHODS: All 
      consecutive patients aged 18 years or older presenting to a single CCL from 
      October 2010 to May 2018 who required E-CPR for CA or refractory CS were 
      included. The primary outcome of our study was overall survival 30 days from 
      VA-ECMO initiation. Secondary outcomes included 1-year survival, hospital length 
      of stay, and ECMO related complications. RESULTS: Sixty-two patients with a mean 
      age of 60 +/- 9 years, 63% male, were included. VA-ECMO was initiated for CA in 39 
      patients (63%) and for CS in 23 patients (37%). The median ECMO duration was 
      48 hr. Overall 30-day survival was 47% (CA group 44% vs. CS group 52%; p = .414). 
      One-year survival was 44%. Initial serum creatinine (OR 1.18 per 10 mumol/L 
      increase; p = .016; AUC = 0.65) was the only multivariate predictor of 30-day 
      mortality. CONCLUSIONS: The use of VA-ECMO in the CCL is feasible, demonstrating 
      47% 30-day survival, largely persistent to 1 year, in a cohort that otherwise has 
      extremely high mortality.
CI  - (c) 2019 Wiley Periodicals, Inc.
FAU - Parr, Christopher J
AU  - Parr CJ
AUID- ORCID: 0000-0003-2452-3327
AD  - Section of Cardiology, Department of Internal Medicine, Max Rady College of 
      Medicine, University of Manitoba, Winnipeg, Manitoba, Canada.
AD  - Cardiac Sciences Program, St. Boniface Hospital, Winnipeg, Manitoba, Canada.
FAU - Sharma, Rajat
AU  - Sharma R
AD  - Division of Cardiology, Department of Medicine, Faculty of Medicine, University 
      of British Columbia, Vancouver, British Columbia, Canada.
FAU - Arora, Rakesh C
AU  - Arora RC
AD  - Cardiac Sciences Program, St. Boniface Hospital, Winnipeg, Manitoba, Canada.
AD  - Department of Surgery, Max Rady College of Medicine, University of Manitoba, 
      Winnipeg, Manitoba, Canada.
FAU - Singal, Rohit
AU  - Singal R
AD  - Cardiac Sciences Program, St. Boniface Hospital, Winnipeg, Manitoba, Canada.
AD  - Department of Surgery, Max Rady College of Medicine, University of Manitoba, 
      Winnipeg, Manitoba, Canada.
FAU - Hiebert, Brett
AU  - Hiebert B
AD  - Cardiac Sciences Program, St. Boniface Hospital, Winnipeg, Manitoba, Canada.
FAU - Minhas, Kunal
AU  - Minhas K
AD  - Section of Cardiology, Department of Internal Medicine, Max Rady College of 
      Medicine, University of Manitoba, Winnipeg, Manitoba, Canada.
AD  - Cardiac Sciences Program, St. Boniface Hospital, Winnipeg, Manitoba, Canada.
LA  - eng
PT  - Journal Article
DEP - 20190905
PL  - United States
TA  - Catheter Cardiovasc Interv
JT  - Catheterization and cardiovascular interventions : official journal of the 
      Society for Cardiac Angiography & Interventions
JID - 100884139
SB  - IM
CIN - Catheter Cardiovasc Interv. 2020 Sep 1;96(3):556-557. PMID: 32935947
MH  - Aged
MH  - *Cardiac Catheterization
MH  - *Cardiopulmonary Resuscitation/adverse effects/mortality
MH  - Coronary Angiography
MH  - *Extracorporeal Membrane Oxygenation/adverse effects/mortality
MH  - Female
MH  - Heart Arrest/diagnosis/mortality/physiopathology/*therapy
MH  - Hospital Mortality
MH  - Humans
MH  - Length of Stay
MH  - Male
MH  - Middle Aged
MH  - Percutaneous Coronary Intervention
MH  - Retrospective Studies
MH  - Risk Assessment
MH  - Risk Factors
MH  - Shock, Cardiogenic/diagnosis/mortality/physiopathology/*therapy
MH  - Time Factors
MH  - Treatment Outcome
OTO - NOTNLM
OT  - cardiac catheterization
OT  - cardiopulmonary resuscitation
OT  - extracorporeal membrane oxygenation
OT  - percutaneous coronary intervention
OT  - resuscitation
EDAT- 2019/09/06 06:00
MHDA- 2021/04/07 06:00
CRDT- 2019/09/06 06:00
PHST- 2019/05/26 00:00 [received]
PHST- 2019/08/16 00:00 [revised]
PHST- 2019/08/25 00:00 [accepted]
PHST- 2019/09/06 06:00 [pubmed]
PHST- 2021/04/07 06:00 [medline]
PHST- 2019/09/06 06:00 [entrez]
AID - 10.1002/ccd.28492 [doi]
PST - ppublish
SO  - Catheter Cardiovasc Interv. 2020 Sep 1;96(3):547-555. doi: 10.1002/ccd.28492. 
      Epub 2019 Sep 5.